Decoy Therapeutics Inc.

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across many viruses. Built on the proprietary IMP3ACT platform, which combines AI-enabled design and rapid synthesis, Decoy develops peptide antivirals designed to move faster toward…More the clinic and expand what is possible in viral prevention and treatment. The company's lead candidates target many respiratory viruses, addressing the health and societal burden of viral disease.